Teva Pharmaceutical Industries (TEVA) – Investment Analysts’ Recent Ratings Updates

Teva Pharmaceutical Industries (NYSE: TEVA) has recently received a number of price target changes and ratings updates:

• 10/20/2026 – Teva Pharmaceutical Industries was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/15/2026 – Teva Pharmaceutical Industries had its price target raised by Barclays from $42.00 to $47.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Teva Pharmaceutical Industries had its price target raised by JPMorgan Chase & Co. from $40.00 to $50.00. They now have an “overweight” rating on the stock.
• 10/9/2026 – Teva Pharmaceutical Industries had its price target raised by Oppenheimer from $50.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/8/2026 – Teva Pharmaceutical Industries was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 10/1/2026 – Teva Pharmaceutical Industries is now covered by TD Cowen. They set a “buy” rating and a $55.00 price target on the stock.
• 9/23/2026 – Teva Pharmaceutical Industries is now covered by Oppenheimer. They set an “outperform” rating and a $50.00 price target on the stock.
• 9/9/2026 – Teva Pharmaceutical Industries is now covered by Leerink Partners. They set an “outperform” rating and a $45.00 price target on the stock.
• 9/8/2026 – Teva Pharmaceutical Industries was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 9/4/2026 – Teva Pharmaceutical Industries had its price target raised by UBS Group from $42.00 to $48.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 374,959 shares of company stock valued at $14,644,285 in the last three months. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.